Consider long positions in biotech stocks Spruce Biosciences (SPRB) and Sarepta Therapeutics (SRPT), which are highlighted as high-conviction bullish picks. For a specific bearish trade, look into buying the November $4 puts on Capricor Therapeutics (CAPR), which has a potential downside target near $1.80 per share. A strong bearish view is also held against the entire quantum computing sector, suggesting investors short stocks like IonQ (IONQ) and D-Wave (QBTS). Another high-conviction short idea mentioned is Joby Aviation (JOBY), which is viewed as a potential scam. The overarching theme is to be cautious and consider shorting over-hyped and crowded trades in the current market.

Quantum Sector (IONQ, D-WAVE)

• The speaker expresses a strong bearish sentiment towards the quantum computing sector, which includes companies like IonQ (IONQ) and D-Wave (QBTS).
• He is actively shorting the sector, stating, "my portfolio is short quantum stocks" and "My P&L is just 100% tied to quantum at this point."
• He seems to be cheering for the stocks to fall, saying, "Let's go, IonQ. Let's go, D-Wave. Keep dropping, baby."
• He believes the recent rally in quantum stocks is temporary and is "coming back down."
• He expresses a strong opinion that the sector is about to "collapse" and that investors will be disappointed because he feels the "government will never invest in quantum."

Takeaways

• The speaker is heavily invested in a short position against the quantum computing sector.
• This is a high-conviction, bearish trade based on the belief that the sector is overhyped and lacks fundamental support (like government investment).
• Investors should be aware of this strong negative sentiment and the potential for high volatility in these stocks.

Capricor Therapeutics (CAPR)

• The speaker refers to this stock as "Capper" or "Capra" and is analyzing it for a short trade.
• He is considering buying November puts as a way to bet against the stock, specifically mentioning the $4 strike price puts ("I like those four plates. They're not bad.").
• He performs a quick valuation analysis, suggesting the stock could trade below its cash per share value. He calculates a potential price of $1.80 based on a "six months below cash" scenario.
• He notes that he is "starting to build it up. I added to it today," referring to his short position.
• A key risk factor for this trade is the timing of the company's Q3 earnings report. If the news comes out after the November 21st options expiration, the puts could expire worthless.

Takeaways

• The speaker has a bearish outlook on CAPR and is actively building a short position.
• A potential trade idea mentioned is buying the November $4 puts.
• The investment thesis is based on a valuation analysis suggesting the stock is overvalued and could trade down to its cash levels, around $1.80 per share.
• This is a speculative, short-term trade with significant risk tied to the timing of company news.

Spruce Biosciences (SPRB)

• The speaker is extremely bullish on Spruce Biosciences.
• He refers to it as the "spruce moose" and expresses a very strong, long-term conviction.
• He mentions a speculative, dream-like price target: "one day we'll wake up and spruce is 300 or something and i won't be dreaming".
• He acknowledges that "Most people think that OI drug doesn't work but it could have a surprise."

Takeaways

• SPRB is a high-conviction, long-term bullish pick for the speaker.
• The investment is a contrarian bet on a potential "surprise" from their drug, despite general market skepticism.
• The $300 price mention is not a formal price target but illustrates the magnitude of the upside he speculates is possible.

Sarepta Therapeutics (SRPT)

• The speaker has a clear bullish stance on Sarepta.
• He states simply and directly, "I like Sarepta. Sarepta is my stock."

Takeaways

• SRPT is a favored stock in the speaker's biotech portfolio. This is a straightforward bullish endorsement.

NVIDIA (NVDA)

• The speaker's sentiment is mixed and largely observational, not outright bullish at its current price.
• He acknowledges its strong performance, noting its price hitting $201 and $203.
• He mentions a news alert that NVIDIA will build AI supercomputers for the U.S. Energy Department and has $500 billion in bookings, a number he seemed surprised by.
• He is skeptical of the hype around Jensen Huang's (NVIDIA CEO) interest in quantum, suggesting Jensen is just trying to sell GPUs to quantum companies rather than being truly invested in the technology.
• He offers a word of caution: "Expensive stocks just have a tendency to drop. There's not always a cause and effect that you can tease out."

Takeaways

• While acknowledging NVIDIA's market dominance and impressive business wins, the speaker implies caution is warranted due to its high valuation.
• The commentary suggests that while NVIDIA is a powerful company, its stock price may be vulnerable to a correction simply because it is expensive.

Other Stock Mentions

• Abivax (ABVX): Bullish. Mentioned alongside Sarepta as a stock he likes.
• Immunovant (IMBX): Bullish regret. The speaker sold his position on Friday after being "scared" by someone else, implying he regrets selling and was previously bullish.
• Intellia Therapeutics (NTLA): Negative risk factor. He mentions a significant negative catalyst: "Intellia Patient died or is dying."
• Joby Aviation (JOBY): Bearish. He states, "I do think Joby is a scam too."
• Humacyte (HUMA): Bearish. He mocks the company for an "oversubscribed deal for warrants," suggesting it's a sign of weakness, not strength.
• Anavex Life Sciences (AVXL): Complex/Sarcastic. He calls it "scam-a-backs" but then says, "If I could go back, I'd go long-long." This likely indicates he views the company as low quality but regrets missing a past run-up in the stock price.
• Bitcoin (BTC): Extremely Bearish. He is very dismissive, saying "bitcoin what is this bitcoin fuck off". He also mentions he is "still working on cracking Bitcoin when I have free time."

Investment Themes & Portfolio Strategy

• Overall Stance: The speaker's current portfolio is "all short." This indicates a very bearish view of the market or specific sectors.
• Short Crowded Trades: He advises against following the herd, stating, "I would short the crowded trades. If you're the last person in the trade, you're the sucker, not the genius."
• Market Valuation: He believes stocks, in general, look overvalued.
• Tokenization of Real Estate: He is highly skeptical of this theme, calling it "not cool" and stating that a property deed is already a form of tokenization.
• Biotech Focus: A significant portion of the discussion revolves around specific biotech stocks (SRPT, SPRB, CAPR, IMBX, NTLA, AVXL), indicating this is a primary area of focus for both long and short ideas.